Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Comparison of Ante- and Post-Mortem PSA Levels for Epidemiological Studies

RICHARD F. JONES, ROBERT SUNHEIMER, HENRY FRIEDMAN, DAVID MILLER, RONALD GINSBURG, MARY JUMBELIC, GREGORY THREATTE and GABRIEL P. HAAS
Anticancer Research March 2005, 25 (2B) 1263-1267;
RICHARD F. JONES
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jonesr@upstate.edu
ROBERT SUNHEIMER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HENRY FRIEDMAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAVID MILLER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RONALD GINSBURG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARY JUMBELIC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GREGORY THREATTE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GABRIEL P. HAAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 25 no. 2B 1263-1267
PubMed 
15865076

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received February 7, 2005
  • Accepted February 28, 2005
  • Published online March 1, 2005.

Copyright & Usage 
Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. RICHARD F. JONES1,3,
  2. ROBERT SUNHEIMER2,
  3. HENRY FRIEDMAN3,
  4. DAVID MILLER4,
  5. RONALD GINSBURG4,
  6. MARY JUMBELIC5,
  7. GREGORY THREATTE2 and
  8. GABRIEL P. HAAS1,3
  1. 1Department of Urology, Upstate Medical University, Syracuse, NY 13210
  2. 2Department of Clinical Pathology, Upstate Medical University, Syracuse, NY 13210
  3. 3VA Medical Center, Syracuse, NY 13210
  4. 4VA Medical Center, Albany, NY 12208
  5. 5Onondaga County Medical Examiners Office, Syracuse, NY 13210, U.S.A.
  1. Correspondence to: Richard F. Jones, PhD, Dept. Urology, Upstate Medical University, 750 E. Adams, Syracuse, NY 13210, U.S.A. Fax: 315-464-6117, e-mail: jonesr{at}upstate.edu

Cited By...

  • 8 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (2B)
Anticancer Research
Vol. 25, Issue 2B
1 Mar 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of Ante- and Post-Mortem PSA Levels for Epidemiological Studies
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
13 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Comparison of Ante- and Post-Mortem PSA Levels for Epidemiological Studies
RICHARD F. JONES, ROBERT SUNHEIMER, HENRY FRIEDMAN, DAVID MILLER, RONALD GINSBURG, MARY JUMBELIC, GREGORY THREATTE, GABRIEL P. HAAS
Anticancer Research Mar 2005, 25 (2B) 1263-1267;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Comparison of Ante- and Post-Mortem PSA Levels for Epidemiological Studies
RICHARD F. JONES, ROBERT SUNHEIMER, HENRY FRIEDMAN, DAVID MILLER, RONALD GINSBURG, MARY JUMBELIC, GREGORY THREATTE, GABRIEL P. HAAS
Anticancer Research Mar 2005, 25 (2B) 1263-1267;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire